MK-677 (Ibutamoren): Complete Research Profile — Oral GH Secretagogue, Mechanism, Clinical Data

What Is MK-677 (Ibutamoren)?

MK-677, also known as ibutamoren or ibutamoren mesylate (MK-677 is the compound designation; ibutamoren is the INN), is a non-peptide, orally bioavailable growth hormone secretagogue that mimics the action of the endogenous ghrelin hormone at its receptor. With a molecular weight of approximately 624.8 Da and an oral bioavailability sufficient for clinical dosing without injection, MK-677 occupies a unique niche in growth hormone research: it is technically not a peptide at all, but rather a small molecule (peptidomimetic) that activates peptide hormone receptors.

For dosing, reconstitution, and protocol details, see our MK-677 (Ibutamoren) Dosage Guide: Research Protocols, Timing & Cycling (2026).

Developed by Merck & Co. (hence the "MK" designation) and later advanced through research collaborations including with Novo Nordisk, MK-677 has been studied in multiple phase 2 clinical trials for applications including growth hormone deficiency, muscle wasting, osteoporosis, and age-related GH decline, but has not received FDA approval for any indication. It remains one of the most extensively studied orally active GH-stimulating compounds in the scientific literature.

For researchers, MK-677's oral bioavailability, once-daily dosing, and well-characterized pharmacology make it an invaluable tool for studying the growth hormone axis, IGF-1 signaling, body composition, sleep architecture, and metabolic regulation.

---

Why "Not a Peptide": Classification and Terminology

A common point of confusion in MK-677 research is its classification. Unlike growth hormone-releasing peptides (GHRPs) such as GHRP-2 or GHRP-6, or growth hormone-releasing hormone (GHRH) analogues such as sermorelin, MK-677 is a non-peptide small molecule.

Specifically, MK-677 is classified as a:

• •Growth hormone secretagogue (GHS): It stimulates GH secretion without directly providing exogenous GH
• •Ghrelin receptor agonist / GH secretagogue receptor (GHS-R1a) agonist: It binds the ghrelin receptor — the receptor that endogenous ghrelin (a peptide hormone) also binds
• •Peptidomimetic: It mimics the biological actions of a peptide (ghrelin) using a non-peptide molecular scaffold

This distinction matters practically because:

• •MK-677 is orally bioavailable — unlike peptide GHRPs/GHSs which are degraded in the GI tract and require injection
• •MK-677 is not detected by standard peptide immunoassays
• •Its pharmacokinetics follow small-molecule rules (hepatic metabolism, renal excretion) rather than peptide metabolism

Classification in sports anti-doping context: Despite being a small molecule, WADA (World Anti-Doping Agency) classifies MK-677 as a prohibited substance under the GH secretagogues category, alongside peptide GHRPs.

---

Molecular Structure and Pharmacological Properties

Chemical Characteristics

Why Oral Bioavailability Is Exceptional

Peptide growth hormone secretagogues (like GHRP-2 or hexarelin) have near-zero oral bioavailability because:

1. Proteases in the stomach and small intestine cleave peptide bonds

2. First-pass hepatic degradation eliminates residual peptide

MK-677 circumvents this entirely because its non-peptide scaffold lacks peptide bonds susceptible to peptidase cleavage, while its molecular design optimizes membrane permeability for intestinal absorption.

---

Mechanism of Action: Ghrelin Receptor Agonism

The Ghrelin System

Ghrelin is a 28-amino-acid acylated peptide hormone primarily secreted by X/A-like cells in the gastric fundus. Its receptor, GHS-R1a (growth hormone secretagogue receptor type 1a), is a GPCR expressed in:

• •Anterior pituitary somatotrophs: Primary site mediating GH secretion
• •Hypothalamus (arcuate nucleus, ventromedial and paraventricular nuclei): Stimulating GHRH release and suppressing somatostatin
• •Hippocampus and other brain regions: Mediating cognitive and behavioral effects
• •Liver, adipose tissue, skeletal muscle: Peripheral metabolic effects
• •Heart and vasculature: Cardiovascular effects

How MK-677 Stimulates GH Release

MK-677 acts as a high-affinity GHS-R1a agonist, with binding affinity comparable to native ghrelin. Upon receptor activation:

1. Pituitary: MK-677 directly stimulates somatotroph cells to release GH via cAMP-independent pathways (primarily Gq/phospholipase C/PKC signaling, plus IP3-mediated calcium release)

2. Hypothalamus: Simultaneously, MK-677 stimulates hypothalamic neurons to release GHRH and suppresses somatostatin (the inhibitory GH regulator) — this dual hypothalamic effect amplifies GH secretion

3. Synergy with GHRH: The combination of direct pituitary stimulation + enhanced GHRH + reduced somatostatin creates a greater-than-additive GH pulse amplification compared to either alone

IGF-1 Elevation: Secondary Effect

GH secreted in response to MK-677 travels to the liver, where it stimulates hepatic IGF-1 (insulin-like growth factor 1) production via GH receptor (GHR) activation. Elevated IGF-1 then mediates many of MK-677's downstream effects on muscle protein synthesis, bone metabolism, and other tissues.

Critically, MK-677 increases IGF-1 levels durably and dose-dependently, even with chronic daily administration — unlike pulsatile GH administration, which produces feedback-driven IGF-1 plateau. This sustained IGF-1 elevation is a key feature distinguishing MK-677's pharmacodynamic profile.

Pulsatile vs Tonic GH Stimulation

Endogenous GH is released in distinct pulses (approximately 5–9 per day), with the largest pulse occurring during slow-wave sleep. MK-677 treatment:

• •Amplifies the amplitude of individual GH pulses rather than converting pulsatile release to tonic/continuous GH
• •Preserves the pulsatile pattern — important because pulsatile GH release is necessary for normal physiological effects (continuous GH exposure, as seen in acromegaly, produces pathological changes)
• •The largest augmentation occurs during the endogenous nocturnal GH pulse, amplifying the physiologically normal sleep-associated GH surge

---

Clinical Trial Evidence: GH and IGF-1 Effects

Dose-Response Relationship

From the foundational phase 1/2 dose-response study (Patchett et al.; Chapman IM et al.):

Single dose pharmacodynamics (MK-677 25mg orally):

• •Peak GH: Mean 10–12 mIU/L (vs ~2–4 mIU/L baseline)
• •Duration of GH elevation: 4–6 hours
• •IGF-1: No acute change (24–48 hours required for hepatic IGF-1 synthesis)

12-month daily administration (MK-677 25mg) in elderly subjects (Chapman IM et al., NEJM 1996):

• •IGF-1: +55% increase (from baseline ~107 ng/mL to ~159 ng/mL)
• •GH pulse amplitude: +97% increase
• •24-hour GH AUC: +79% increase
• •Body weight: +2.7 kg (vs +0.5 kg placebo)
• •Fat-free mass (by DEXA): +1.7 kg increase
• •Fat mass: no significant change

---

Clinical Trial Evidence: Body Composition

Lean Mass Preservation in Caloric Restriction

Design: Double-blind, placebo-controlled crossover study; MK-677 25mg vs placebo in healthy young men during 2-day caloric restriction (diet providing 18 kcal/kg body weight) to examine GH's role in protein anabolism during fasting (N=24) (Svensson et al., J Clin Endocrinol Metab 1998)

Results:

• •MK-677 reversed protein catabolic effects of caloric restriction
• •Nitrogen balance: +2.9 g/day (MK-677) vs −1.3 g/day (placebo) during restriction
• •IGF-1: +70% vs +3%
• •Demonstrates that GH/IGF-1 axis activation by MK-677 has significant protein-sparing effects

2-Month Trial in Obese Subjects

Design: Parallel-group, double-blind; MK-677 25mg daily vs placebo; 8 weeks; obese subjects (N=24)

Results (MK-677 vs placebo):

• •IGF-1: +52% vs −1%
• •IGFBP-3: +37% vs +3% (consistent with GH axis activation)
• •Resting metabolic rate (RMR): +15% increase in 24-hour energy expenditure
• •Fat-free mass: +2.5 kg vs +0 kg
• •Fat mass: −1.0 kg vs +0.2 kg (trending)
• •No significant adverse effects at 8 weeks

Sarcopenia and Hip Fracture Recovery

Design: 2-year randomized trial; MK-677 25mg vs placebo in healthy elderly subjects aged 60–81 (N=65) — one of the longest MK-677 studies

Results (2-year data, Nass et al., J Clin Endocrinol Metab 2008):

• •GH pulse amplitude: sustained increase over 2 years
• •IGF-1: sustained +40–50% elevation over 2 years (no tachyphylaxis)
• •Fat-free mass: +1.5 to 2.0 kg sustained
• •Fat mass: +1.0 to 1.5 kg increase (limitation)
• •Stair climbing power: no significant improvement
• •Quality of life (QoL score): no significant change vs placebo

Key finding: IGF-1 elevation was maintained without attenuation over 2 years — important evidence against long-term tachyphylaxis to MK-677's GH-stimulating effects.

Reference: Nass R, et al. "Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial." Ann Intern Med. 2008;149(9):601–611. PMID: 18981485

---

Clinical Trial Evidence: Sleep Quality

Sleep Architecture Enhancement

One of the most reproducible effects of MK-677 in research subjects is improvement in sleep architecture, particularly slow-wave sleep (SWS), which is the sleep stage associated with physiological GH release.

Phase 1 study of sleep architecture (Copinschi et al., Sleep 1996):

Design: Healthy young and elderly subjects; MK-677 25mg vs placebo; two 14-day periods crossover; polysomnography assessment

Results (MK-677 vs placebo):

• •Slow-wave sleep (SWS) duration: +50% increase in elderly subjects; +20% in young subjects
• •REM sleep duration: preserved or slightly increased
• •Total sleep time: minor improvement
• •Sleep onset: no significant change
• •Nighttime GH pulse amplitude: Dramatically increased (aligning with augmented SWS)
• •Wake after sleep onset: reduced

Clinical significance: The relationship between SWS and GH is bidirectional — GH release augments SWS, and SWS augments GH release. MK-677 appears to enhance this cycle by amplifying the nocturnal GH pulse, increasing SWS, which may in turn facilitate deeper rest.

This effect is particularly relevant for elderly research subjects where SWS decline is a known feature of aging associated with reduced GH secretion, impaired memory consolidation, and metabolic changes.

Reference: Copinschi G, et al. "Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man." Neuroendocrinology. 1997;66(4):278–286. PMID: 9349662

---

Clinical Trial Evidence: Bone Density

Effects on Bone Metabolism Markers

Design: 12-month study; MK-677 25mg vs placebo in elderly subjects (N=187) — substudy of a larger aging trial

Results:

• •Bone formation markers (osteocalcin, bone-specific alkaline phosphatase): significant increases (20–30%)
• •Bone resorption markers (urinary NTX, CTX): also increased (bone turnover increased overall)
• •Bone mineral density (BMD by DEXA): modest, non-significant trends toward increase at 12 months
• •Longer-term BMD studies suggest 18–24 months may be needed to observe statistically significant BMD changes

Hip Fracture Study:

The GSFII (Growth Hormone Secretagogue in Frail Elderly) trial examined MK-677 in elderly patients recovering from hip fracture:

• •Design: MK-677 25mg vs placebo in 123 elderly hip fracture patients for 6 months
• •Results: Reduced rehabilitation time; improved functional recovery scores; no significant bone density changes at 6 months
• •IGF-1: Normalized to younger adult levels from subnormal baseline in treated patients

---

Safety Profile

Well-Characterized in Clinical Trials (Up to 2 Years)

Because MK-677 has been extensively studied in phase 2 trials, its adverse event profile is better characterized than many research compounds.

Insulin Resistance and Blood Glucose

The most clinically significant concern with MK-677 is insulin resistance and fasting glucose elevation:

From the 2-year Nass et al. trial:

• •Fasting glucose: Increased by approximately 7 mg/dL (from ~97 to ~104 mg/dL) in treated vs placebo
• •Fasting insulin: Increased by ~20–30%
• •HOMA-IR (insulin resistance index): Significant increase
• •Mechanism: GH induces hepatic insulin resistance as a physiological counter-regulatory mechanism; this is expected with any chronic GH elevation
• •Clinical concern: In individuals with pre-existing insulin resistance, T2DM risk, or impaired fasting glucose, MK-677 may precipitate or worsen glycemic control
• •Reversibility: Insulin sensitivity returns to baseline after discontinuation

Researcher note: The insulin resistance observed with MK-677 is a class effect of GH elevation — not unique to MK-677. The same effect is seen with exogenous GH administration. This partially counteracts the anabolic benefits on body composition by promoting some fat accumulation alongside muscle gain.

Edema (Fluid Retention)

• •Peripheral edema: ~27–33% of MK-677-treated subjects in trials (vs ~5% placebo)
• •Mechanism: GH-induced sodium retention via IGF-1's renal tubular effects
• •Typically mild to moderate; carpal tunnel syndrome (from fluid accumulation in the carpal tunnel) was observed in some subjects
• •Generally reversible upon dose reduction or discontinuation
• •Caution in patients with heart failure or compromised renal function

Increased Appetite

• •Ghrelin mimicry at GHS-R1a produces orexigenic (appetite-stimulating) effects — this is a direct pharmacological effect of ghrelin receptor activation
• •Increased appetite: reported in ~22–33% of subjects
• •Relevant for body composition research: caloric intake may increase, potentially offsetting fat loss effects
• •For subjects targeting lean mass gain, the appetite stimulation may be considered a favorable effect

Fatigue and Lethargy

• •Mild fatigue, particularly in early treatment weeks: ~15–20%
• •Often attributed to the initial phase of GH axis stimulation
• •Typically diminishes with 2–4 weeks of continued use

Morning Cortisol and Prolactin

• •Slight increases in morning cortisol (by ~10–15%) without clinical significance
• •Modest prolactin increases in some studies; below pathological thresholds
• •No significant effect on thyroid hormones (TSH, T4, T3)
• •No effect on LH, FSH, testosterone, or estradiol

Cardiovascular Safety

From the 2-year trial data:

• •No increase in adverse cardiovascular events vs placebo
• •Mild heart rate increase (~2–4 bpm) — possible GH-mediated effect
• •Blood pressure: no clinically significant change

Long-Term Safety (Beyond 2 Years)

No studies exceeding 2 years have been published. Long-term effects on:

• •GH axis suppression/desensitization after discontinuation: not well characterized
• •Potential promotion of existing undiagnosed tumors (GH can promote certain cancers): theoretical concern
• •Acromegaly-like features with sustained supra-physiological IGF-1: would require years of very high exposure

Contraindications/precautions:

• •Active cancer or history of cancer (GH is trophic for many cancer cell types)
• •Diabetic retinopathy
• •Significant insulin resistance or T2DM
• •Severe fluid retention disorders

---

MK-677 vs Peptide Growth Hormone Secretagogues

A key research question is how MK-677 compares to injectable peptide GHSs (GHRP-2, GHRP-6, hexarelin, ipamorelin) in GH-stimulating potency and safety:

MK-677's oral route is a significant practical advantage for chronic research protocols. Ipamorelin is generally preferred when selectivity is paramount (minimal cortisol/prolactin), while MK-677 is preferred when oral administration is required.

For comparison of MK-677 with other growth hormone secretagogues, see our Growth Hormone Secretagogues Compared guide.

---

Why Researchers Use MK-677

MK-677 occupies a specific research niche for several reasons:

1. Oral bioavailability: Eliminates injection requirement, simplifying chronic research protocols and improving compliance in long-duration studies

2. Sustained IGF-1 elevation: Unlike exogenous GH or pulsatile peptide GHRPs, MK-677's long half-life produces sustained and reproducible IGF-1 elevation with once-daily dosing

3. Non-peptide nature: Easier synthesis, more stable formulation, longer shelf life than peptide-based GHRPs

4. Extensive safety data: 2-year human trial data provide an unusually robust safety database for a research compound

5. Sleep research tool: The documented SWS enhancement makes it valuable for studying sleep architecture and GH's relationship to sleep

Research applications include:

• •GH deficiency models (studying GH axis restoration)
• •Age-related GH decline (somatopause)
• •Sarcopenia and muscle wasting research
• •Osteoporosis and bone turnover studies
• •Sleep architecture and circadian biology research
• •Body composition modification in controlled settings

---

Regulatory Status

MK-677 has not received FDA approval for any indication. Merck pursued it through phase 2 trials in the 1990s–2000s but did not advance to phase 3. The compound is:

• •Not scheduled under the Controlled Substances Act (not a controlled substance in the US as of 2025)
• •Prohibited by WADA in sport (class S2 — peptide hormones, growth factors, related substances and mimetics)
• •Research chemical status in most jurisdictions — legal to purchase and possess for research purposes, but not for human consumption
• •Sold under various names in supplement markets (often as "ibutamoren" or "MK-677"), despite not being FDA-approved

---

Dosing Research Protocols

Important disclaimer: The following information is published from clinical trial protocols for educational reference only. MK-677 is not approved for human use.

Standard Research Doses (from Clinical Trials)

Administration: Once daily, oral (tablet or capsule). Taking at night may leverage the natural nocturnal GH pulse, though studies show efficacy with morning or evening dosing.

Duration of studies: Clinical trials have run 1 month to 2 years. Chronic administration is required to sustain IGF-1 elevation.

Research Storage and Handling

---

Tools for Researchers

• •Peptide Dose Calculator: Calculate research doses and concentrations
• •Growth Hormone Secretagogues Compared: Cross-compound analysis of GHRPs, GHRHs, and GHSs
• •Peptide Half-Life Complete Reference Guide: Pharmacokinetic reference for research planning

---

Key Research References

2. Nass R, et al. "Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial." Ann Intern Med. 2008;149(9):601–611. PMID: 18981485

4. Copinschi G, et al. "Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man." Neuroendocrinology. 1997;66(4):278–286. PMID: 9349662

6. Patchett AA, et al. "Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue." Proc Natl Acad Sci USA. 1995;92(15):7001–7005. PMID: 7624358

7. Thorner MO, et al. "Acceleration of growth in two children treated with human growth hormone releasing hormone." N Engl J Med. 1985;312(1):4–9. [Background context on GH secretagogue development]

---

Research Disclaimer

The content on this page is intended for educational and informational purposes for the scientific research community only. MK-677 (ibutamoren) has not been approved by the FDA or any equivalent regulatory authority for human therapeutic use. It is not approved for self-administration, athletic performance enhancement, or use outside of supervised research or clinical trial settings.

All clinical data referenced is derived from published, peer-reviewed research. Peptides.SO does not provide medical advice, diagnose conditions, or recommend treatments. Researchers and consumers should consult qualified healthcare professionals for all medical decisions.

Compounds sold through verified suppliers on Peptides.SO are sold for laboratory research use only (RUO) and are not intended for human consumption, therapeutic use, or veterinary administration.

---

Further Reading:

• •Ipamorelin: The Selective Growth Hormone Secretagogue — Complete Research Profile
• •Ghrelin: The Acylated Gastric Peptide Driving Growth Hormone, Energy Homeostasis, and Neuroprotection Research
• •GHRP-6: The Original Growth Hormone Releasing Peptide — Complete Research Profile
• •GHRP-2 (Pralmorelin): The Potent Second-Generation Growth Hormone Secretagogue — Complete Research Profile
• •Peptide Stack Builder
• •Dosage Chart